首页|不同方案预防气滞血瘀证子宫内膜息肉患者宫腔镜下切除术后复发的临床效果观察

不同方案预防气滞血瘀证子宫内膜息肉患者宫腔镜下切除术后复发的临床效果观察

扫码查看
目的 观察不同方案预防气滞血瘀证子宫内膜息肉(EPs)患者宫腔镜下切除术后复发的临床效果。方法 280 例行宫腔镜下切除术的气滞血瘀证EPs患者,根据术后预防复发方案不同分为地屈孕酮组(术后口服地屈孕酮,60 例)、地屈孕酮+中药组(术后口服地屈孕酮+中药,75 例)、曼月乐组[术毕宫腔置入左炔诺孕酮宫内节育系统(商品名:曼月乐),68 例]、曼月乐+中药组(术毕宫腔置入曼月乐+术后口服中药,77 例)。比较四组不同时间子宫内膜厚度、月经量及复发率。结果 术后12 个月,地屈孕酮组子宫内膜厚度、月经失血图(PBAC)评分分别为(7。48±0。77)mm、(54。70±6。64)分,地屈孕酮+中药组分别为(6。31±1。16)mm、(49。08±6。21)分,曼月乐组分别为(6。85±0。71)mm、(45。46±6。17)分,曼月乐+中药组分别为(5。94±0。64)mm、(39。73±6。17)分;术后 24 个月,地屈孕酮组子宫内膜厚度、PBAC评分分别为(9。59±1。11)mm、(58。14±7。40)分,地屈孕酮+中药组分别为(7。94±1。42)mm、(45。78±7。65)分,曼月乐组分别为(8。86±1。44)mm、(40。66±5。96)分,曼月乐+中药组分别为(7。23±1。74)mm、(38。36±6。48)分。术后 12、24 个月,地屈孕酮+中药组子宫内膜厚度、PBAC评分低于地屈孕酮组,曼月乐+中药组低于曼月乐组(P<0。05);曼月乐组子宫内膜厚度、PBAC评分低于地屈孕酮组,曼月乐+中药组低于地屈孕酮+中药组(P<0。05)。随访 24 个月,地屈孕酮+中药组复发率 8。00%低于地屈孕酮组的 33。33%,曼月乐+中药组复发率 1。30%低于曼月乐组的 13。24%(P<0。05);曼月乐组复发率低于地屈孕酮组(P<0。05)。结论 对气滞血瘀证EPs患者宫腔镜下切除术毕宫腔置入曼月乐+术后口服中药能减少患者月经量,降低子宫内膜厚度,降低复发率,效果明显。
Observation of the clinical effect of different schemes for preventing recurrence of endometrial polyps in patients with qi stagnation and blood stasis syndrome after hysteroscopic resection
Objective To observe the clinical effect of different schemes for preventing recurrence of endometrial polyps(EPs)in patients with qi stagnation and blood stasis syndrome after hysteroscopic resection.Methods A total of 280 EPs patients with qi stagnation and blood stasis syndrome who underwent hysteroscopic resection were divided into the dydrogesterone group(postoperative oral dydrogesterone,60 cases),the dydrogesterone+Chinese medicine group(postoperative oral dydrogesterone+Chinese medicine,75 cases),the Mirena group[postoperative intrauterine implantation of the levonorgestrel intrauterine system(trade name:Mirena),68 cases],and the Mirena+Chinese medicine group(postoperative intrauterine implantation of Mirena+postoperative oral Chinese medicine,77 cases)according to different postoperative recurrence prevention protocols.The endometrial thickness,menstrual volume and recurrence rate were compared among the four groups at different time points after surgery.Results At 12 months after surgery,the endometrial thickness and pictorial blood loss assessment chart(PBAC)score were(7.48±0.77)mm and(54.70±6.64)points in dydrogesterone group,(6.31±1.16)mm and(49.08±6.21)points in dydrogesterone+Chinese medicine group,(6.85±0.71)mm and(45.46±6.17)points in Mirena group,and(5.94±0.64)mm and(39.73±6.17)points in Mirena+Chinese medicine group.At 24 months after surgery,the endometrial thickness and PBAC score were(9.59±1.11)mm and(58.14±7.40)points in dydrogesterone group,(7.94±1.42)mm and(45.78±7.65)points in dydrogesterone+Chinese medicine group,(8.86±1.44)mm and(40.66±5.96)points in Mirena group,and(7.23±1.74)mm and(38.36±6.48)points in Mirena+Chinese medicine group.At 12 and 24 months after surgery,the endometrial thickness and PBAC score of dydrogesterone+Chinese medicine group were lower than those of dydrogesterone group,and Mirena+Chinese medicine group was lower than Mirena group(P<0.05).The endometrial thickness and PBAC score of Mirena group were lower than those of dydrogesterone group,and Mirena+Chinese medicine group was lower than dydrogesterone+Chinese medicine group(P<0.05).After 24 months of follow-up,the recurrence rate of dydrogesterone+Chinese medicine group was 8.00%,which was lower than 33.33%of dydrogesterone group;the recurrence rate of Mirena+Chinese medicine group was 1.30%,which was lower than 13.24%of Mirena group(P<0.05).The recurrence rate of Mirena group was lower than that of dydrogesterone group(P<0.05).Conclusion For EPs patients with qi stagnation and blood stasis syndrome,intrauterine implantation of Mirena+oral Chinese medicine after hysteroscopic resection can reduce menstrual volume,endometrial thickness and recurrence rate,and the effect is obvious.

Qi stagnation and blood stasisEndometrial polypsLevonorgestrel intrauterine systemDydrogesteroneChinese medicineHysteroscope

姜薇、贾丹

展开 >

215000 南京中医药大学附属苏州市中医医院妇科

气滞血瘀证 子宫内膜息肉 左炔诺孕酮宫内节育系统 地屈孕酮 中药 宫腔镜

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(24)